Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie

Lublin 20954

1 studies enrolling now · 24 studies all time

What they study most

Acute Coronary Syndrome, Acute Myocardial Infarction, Alzheimer's Disease, Bladder Cancer, CIED Related Infection, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Chronic Kidney Diseases, Lupus Erythematosus, Systemic, Mild Thrombocytopenia, Moderate Thrombocytopenia, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting

Studies at this site

• A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia — Recruiting now
• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis — Running, not enrolling
• A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome — Completed
• A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) — Running, not enrolling
• Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma — Running, not enrolling
• Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% Dual Inactivation and Filtration (DIF) in Participants With Post-polio Syndrome — Stopped early
• Evaluation in STEMI Patients Using FDY-5301 — Completed
• Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD) — Stopped early
• A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE) — Completed
• A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus — Stopped early
• A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 — Stopped early
• Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP — Completed
• A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) — Completed
• Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD) — Completed
• Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease — Stopped early
• Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure — Completed
• Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease — Completed
• 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease — Stopped early
• Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis — Completed
• World-wide Randomized Antibiotic Envelope Infection Prevention Trial — Completed
• Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612) — Completed
• Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) — Completed
• An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab — Completed
• Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer — Stopped early